I’m not sure that’s true for neuro. Proving effectiveness over placebo is where it is hard in such a heterogeneous group. Also phase 2 trials will be complicated. What is the dosing regime, duration, interval, dose. It’s an old molecule but new delivery, effectively starting from scratch. It’s true that non controlled data from 5 patients exists but given the differences I think it’s even less valuable now
- Forums
- ASX - By Stock
- CUV
- Ann: PRENUMBRA formulation completed for clinical trial use
Ann: PRENUMBRA formulation completed for clinical trial use, page-5
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.53 |
Change
0.290(1.90%) |
Mkt cap ! $777.7M |
Open | High | Low | Value | Volume |
$15.35 | $15.55 | $15.03 | $861.9K | 56.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 164 | $15.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.53 | 512 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 164 | 15.380 |
1 | 164 | 15.350 |
1 | 164 | 15.310 |
1 | 164 | 15.280 |
1 | 500 | 15.100 |
Price($) | Vol. | No. |
---|---|---|
15.530 | 512 | 1 |
15.550 | 1755 | 1 |
15.570 | 100 | 1 |
15.590 | 164 | 1 |
15.600 | 1500 | 2 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |